Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch’s Groundbreaking BalanceTutor™ Rehabilitation System
Ekso Bionics (NASDAQ:EKSO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
How Recent Moves Are Rewriting the Story for Ekso Bionics [Yahoo! Finance]
Ekso Bionics (NASDAQ:EKSO) was given a new $6.00 price target on by analysts at HC Wainwright.
Ekso Bionics (NASDAQ:EKSO) had its price target raised by analysts at HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.